ArticleBMJ neurology open2026
Inflammatory biomarkers as predictors of paradoxical reaction in tubercular meningitis: a prospective observational study.
Article in BMJ neurology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tubercular meningitis (TBM) is associated with high morbidity and mortality due to intense inflammatory responses causing basal exudates, vasculitic infarcts, hydrocephalus and cranial nerve palsies. Paradoxical reaction (PR) occurs in nearly 30% of patients and contributes to clinical deterioration during treatment. Dysregulated inflammatory mediators in serum and cerebrospinal fluid (CSF) have been implicated in PR and adverse outcomes in TBM. Objective: This study evaluated baseline serum and CSF inflammatory biomarkers for predicting PR and vasculitic infarcts in newly diagnosed TBM patients. Methods: In this prospective observational study, 151 treatment-naïve TBM patients fulfilling Marais consensus criteria were enrolled. Baseline clinical, radiological, serum and CSF inflammatory markers were assessed and repeated during PR/stroke. Serum markers included high-sensitivity C reactive protein (hsCRP), erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), ferritin, albumin, D-dimer, neutrophil-lymphocyte ratio (NLR) and systemic immune-inflammation index. CSF analysis included adenosine deaminase, NLR, protein, glucose and leucocyte count. Results: Among 151 patients (mean age 32.7±14.5 years), 43 (28.4%) developed PR, most commonly within 1-2 months of antitubercular therapy initiation. Altered sensorium (58.1%) and progression of hydrocephalus (60.5%) were common manifestations. Higher baseline ESR, hsCRP, LDH, ferritin, D-dimer and lower serum albumin were significantly associated with PR. Serum ferritin showed the best predictive accuracy (area under the curve 0.910; cut-off ≥451 µg/L; sensitivity 88.4%, specificity 88.9%). On multivariable analysis, serum ferritin (OR 1.004; p=0.001) and ESR (OR 1.020; p=0.033) remained independent predictors. Conclusions: Serum inflammatory markers, particularly ferritin and ESR, may serve as useful predictors of PR in TBM. These findings support an immune-mediated mechanism underlying paradoxical worsening and may help identify high-risk patients who could benefit from early anti-inflammatory or immune-modulatory therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.